SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced that it will report first quarter 2015 financial results on Thursday, April 30, 2015. A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm ET (1:30 p.m. PT). OXiGENE's earnings conference call can be heard live by dialing (888) 841-3431 (Conference ID: 32409932) in the United States and Canada, and +1 (678) 809-1060 for international callers, five minutes prior to the beginning of the call. To listen to a live or archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investors" tab, select the link to "Events & Presentations." About OXiGENE OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The company's lead clinical product candidate, fosbretabulin, is in development as a potential treatment for solid tumors. OXi4503, its second product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
CONTACT: Investor and Media Contact: email@example.com 650-635-7000